Related Experiment Video
Updated: Jun 21, 2026

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
Are inhaled mRNA vaccines safe and effective? A review of preclinical studies
Evalyne M Jansen1, Henderik W Frijlink1, Wouter Lj Hinrichs1
1Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
Introduction:
Injected mRNA vaccines have been proven effective and safe in the SARS-CoV-2 pandemic. Using the machinery of the cell, mRNA vaccines translate into an antigen, which triggers an adaptive immune response. The effectiveness of intramuscular administered mRNA vaccines wanes in the months post-vaccination, which makes frequent booster administrations necessary. To make booster administration easier and increase efficacy, pulmonary administration could be investigated. The aim of this literature study was therefore to review the published preclinical (animal) studies on the safety and efficacy of pulmonary administered mRNA vaccines.
Areas Covered:
We first provide background information on mRNA vaccines and immunological mechanisms of vaccination. Thereafter, we provide an evaluation of published animal studies, in which mRNA vaccines (or mRNA containing nanoparticles) were delivered into the lungs. We covered the following areas: biodistribution, cellular uptake, immune response, protection, and safety. All relevant papers were found using PubMed/MEDLINE database.
Expert Opinion:
In our opinion, head-to-head comparison studies examining the safety and efficacy of intramuscular injected and pulmonary administered liquid mRNA vaccines should be performed first. When pulmonary delivered mRNA vaccines are shown to be effective and safe, inhalable dry powder formulations should be engineered. Finally, the tolerability of patients with respiratory diseases should be considered.
Insights
Pulmonary mRNA vaccines offer a potential alternative to injections for boosting immunity against SARS-CoV-2. Preclinical studies suggest this delivery method warrants further investigation for improved vaccine efficacy and administration.
Area of Science:
- Immunology
- Vaccinology
- Pulmonary Drug Delivery
Background:
- mRNA vaccines, proven effective for SARS-CoV-2, utilize cellular machinery to produce antigens and elicit immune responses.
- The efficacy of intramuscular mRNA vaccines wanes over time, necessitating frequent booster doses.
- Pulmonary administration presents a potential strategy to enhance vaccine efficacy and simplify booster regimens.
Approach:
- This literature study systematically reviewed preclinical (animal) studies on pulmonary mRNA vaccine administration.
- Searches were conducted in the PubMed/MEDLINE database to identify relevant research.
- Key areas evaluated included biodistribution, cellular uptake, immune response, protection, and safety.
Key Points:
- Pulmonary delivery of mRNA vaccines in animal models has been explored for various immunological parameters.
- Studies assessed how mRNA vaccines distribute within the body, are taken up by cells, and stimulate immune responses after lung delivery.
- The protective effects and safety profiles of pulmonary mRNA vaccination were also examined in preclinical settings.
Conclusions:
- Further research is needed to compare the safety and efficacy of pulmonary versus intramuscular mRNA vaccine administration directly.
- Development of inhalable dry powder formulations for pulmonary mRNA vaccines should be pursued if liquid formulations prove safe and effective.
- The tolerability of pulmonary mRNA vaccines in patients with pre-existing respiratory conditions requires careful consideration.
More Related Videos
Related Concept Videos
Nuclear Export of mRNA
Microorganisms in Medicine and Therapeutics
Vaccines
Respiratory Syncytial Virus Disease

